Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herbalife appointment

This article was originally published in The Tan Sheet

Executive Summary

Newly appointed General Counsel Brett Chapman will address legal matters in all 58 countries where company operates, L.A.-based firm announces. Chapman most recently served as deputy general counsel for The Walt Disney Company. Announcement follows the appointment of another former Disney exec, Gregory Probert, who was named Herbalife's COO in August (1"The Tan Sheet" Aug. 18, 2003, In Brief)...

You may also be interested in...



Herbalife exec

Gregory Probert named chief operating officer, with "overall responsibility" for the supplement marketer's business operations in 58 markets around the world, Herbalife says. He joins Herbalife from DMX Music, where he was president and chief executive officer. He also formerly served as exec VP-COO for Disney's Buena Vista Home Entertainment business. Probert replaces Brian Kane, who is relocating to the UK to take over as president of Herbalife Europe. Probert's appointment follows that of former Nokia Mobile Phones VP Michael Wisk as Herbalife's chief marketing officer (1"The Tan Sheet" July 28, 2003, In Brief)...

Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results

Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.

Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar

Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096112

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel